Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers

Clinical Drug Investigation

Volumn 34, Issue 7, 2014, Pages 475-482

  Yu, Christine Y ^a   Campbell, Stuart E ^b   Sponseller, Craig A ^c   Small, David S ^a   Medlock, Matthew M ^d   Morgan, Roger E ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Kowa Research Institute Inc   (United States)

^c Kowa Pharmaceuticals America Inc   (United States)

^d Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; LACTONE DERIVATIVE; PITAVASTATIN; PITAVASTATIN LACTONE; RITONAVIR; UNCLASSIFIED DRUG; QUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL LABORATORY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HUMAN; LIMIT OF QUANTITATION; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MYALGIA; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETICS; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; ADOLESCENT; BLOOD; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; QUINOLINES; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 84904044827     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0198-x     Document Type: Article

References (27)

1. Global AIDS Overview. http://aids.gov/federal-resources/around-the-world/ global-aids-overview/. Accessed 17 Apr 2014.
2. World Health Organization, Europe, Data and statistics. http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/ data-and-statistics. Accessed 17 Apr 2014.
3. HIV in the United States: at a glance. http://www.cdc.gov/hiv/resources/ factsheets/us.htm. Accessed 17 Apr 2014.
4. Crum NF, Riffenburgh RH, Wegner S, et al for the Triservice AIDS Clinical Consortium. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
5. Palella FJ Jr, Baker RK, Moorman AC, et al., for the HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34.
6. Go AS, Mozaffarian D, Roger VL, et al on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292.
7. Félix-Redondo FJ, Grau M, Fernández-Bergés D. Cholesterol and cardiovascular disease in the elderly. Facts and gaps. Aging Dis. 2013;4:154-69.
8. Giannarelli C, Klein RS, Badimon JJ. Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis. 2011;219:384-9.
9. Dubé MP, Cadden JJ. Lipid metabolism in treated HIV infection. Best Pract Res Clin Endocrinol Metab. 2011;25:429-42.
10. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815-31.
11. FDA Drug Safety Communication. Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury, March 1, 2012. Available from http://www.fda.gov/Drugs/ DrugSafety/ucm293877.htm. Accessed 17 Oct 2013.
12. Duggan ST. Pitavastatin: a review of its use in the management of hypercholesterolemia or mixed dyslipidemia. Drugs. 2012;72:565-84.
13. Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139-46.
14. Hirano M, Maeda K, Shitara Y, et al. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34:1229-36.
15. Choi MK, Shin HJ, Choi YL, et al. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011;41:24-34.
16. ® (darunavir): package insert. Janssen Pharmaceuticals, Inc., Titusville, NJ; 2013.
17. Morgan RE, Campbell SE, Suehira K, et al. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr. 2012;60:158-64.
18. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10:373-87.
19. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117-25.
20. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33:27-41.
21. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42:1048-59.
22. Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol. 2012;52:922-31.
23. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. Eighth International Workshop on Clinical Pharmacology of HIV Therapy. 16-18 April 2007, Budapest, Hungary. Abstract 54
24. Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012;52:1725-38.
25. Nakaya N, Soji N, Kaneko T, et al. Efficacy and safety of NK-104 (pitavastatin), a novel HMG-CoA reductase inhibitor in hypercholesterolemic volunteers. J Clin Ther Med. 2001;17:767-87.
26. Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis. 2007;196:1177-9.
27. De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, et al. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr. 2008;49:179-82.